

ABSTRACT

USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC
FIBROSIS (CF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

5 The invention is based on the finding that the secretin receptor is expressed in tissues present in the distal lung of humans. In patient with CF, levels of the receptor are elevated compared to normal tissue. Treatment of tissue by 10 secretin stimulates the movement of negative ions in the tissue. The invention provides methods of treatment of cystic fibrosis or COPD in a patient by administering to said patient an effective amount of an agent which triggers anion efflux in respiratory tissue via the activation of a secretin receptor.